General
Preferred name
LAQUINIMOD
Synonyms
Laquinimod (ABR-215062) ()
Laquinamod ()
ABR-215062 ()
ABR-215062, LAQ ()
Laquinimod sodium ()
ABR-215062 FREE ACID ()
TV-5600 FREE ACID ()
TV-5600 ()
Laquinimod sodium salt ()
Nerventra ()
ABR-215062 SODIUM ()
P&D ID
PD010572
CAS
248281-84-7
248282-07-7
Tags
available
drug
drug candidate
Approved by
MHRF
First approval
2013
Drug indication
Multiple sclerosis
Crohn's disease
Huntington disease
Primary progressive multiple sclerosis
Lupus
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Laquinimod is an experimental immunomodulator being investigated as an oral treatment for multiple sclerosis (MS) .
(GtoPdb)
DESCRIPTION
Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-¦ÊB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1][2][3][4].
DESCRIPTION
Laquinimod, also known as, is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. Laquinimod seems to be able to reduce the MS disease activity on MRI. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses into MS among patients beyond a placebo. However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing-remitting multiple sclerosis.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
16
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
35
Molecular Weight
356.09
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
3
cLogP
3.56
TPSA
62.54
Fraction CSP3
0.16
Chiral centers
0.0
Largest ring
6.0
QED
0.78
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
NF-¦ÊB
NF-??
CXCL2
Apoptosis
NF-κB
Immunology & Inflammation related
Member status
member
MOA
Immunomodulator
Immunosuppressant
Source data
